Biocon Expands Biosimilar Market Entry for Yesintek™

Biocon Limited has secured market entry for its proposed biosimilar to Stelara®, Yesintek™ (Ustekinumab), in nine additional global markets including Australia, Brazil, China, Hong Kong, Israel, Mexico, New Zealand, South Korea, and Kazakhstan. This agreement with Janssen Sciences Ireland builds upon previous agreements for the US, Europe, UK, Canada, and Japan. Yesintek™ is an interleukin-12 and -23 antagonist approved for treating autoimmune diseases like Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The reference drug, Stelara®, had worldwide sales of $6.08 billion in 2025. This expansion aims to provide affordable treatment options for patients in these new markets, subject to regulatory approvals.